Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity

Gene Therapy

Volumn 7, Issue 10, 2000, Pages 837-843

  Kim, Y S ^a   Sonn, C H ^a   Paik, S G ^a   Bothwell, A L M ^b  

^a Chungnam National University   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 4; Immunotherapy; Tumor immunity

Indexed keywords

CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; RECOMBINANT CYTOKINE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CHIMERA; CYTOKINE RELEASE; FEMALE; FIBROSARCOMA; GENE THERAPY; GENETIC ENGINEERING; LEUKOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH2 CELL; TRANSGENE; TUMOR CELL; TUMOR IMMUNITY;

ANIMALIA;

EID: 0034024202     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301175     Document Type: Article

References (51)

1. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene 'intercrine' cytokine family. Annu Rev Immunol 1991; 9: 617-648.
2. Lloyd AR, Oppenheim JJ. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 1992; 13: 169-172.
3. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 1992; 52: 4853-4857.
4. Modesti A et al. Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated rejection of a spontaneous murine adenocarcinoma. Int J Cancer 1993; 53: 988-993.
5. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704.
6. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995; 270: 908.
7. Tracey KJ et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474.
8. Golumbek PT et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713-716.
9. Forni G et al. Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. J Immunother 1993; 14: 253-257.
10. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
11. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annn Rev Immunol 1995; 13: 399-415.
12. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin(IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
13. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Nntl Acad Sci USA 1993; 90: 3539-3543.
14. Tjuvajev J et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res 1995; 154: 1902-1910.
15. Lollini PL et al. Systemic effects of cytokines released by gene-transduced tumor cells: marked hyperplasia induced in small bowel by γ-interferon transfectants through host's lymphocytes. Int J Cancer 1995; 61: 425-430.
16. Nahill SR, Welsh RM. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response. J Exp Med 1993; 177: 317-327.
17. Zheng P, Liu Y. Costimulation by B7 modulates specificity of cytotoxic T lymphocytes: a missing link that explains some bystander T cell activation. J Exp Med 1997; 186: 1787-1791.
18. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
19. Rivoltini L et al. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res 1990; 50: 5551-5557.
20. Colombo MP, Forni G. Immunotherapy I: cytokine gene transfer strategies. Cancer Metast Rev 1997; 16: 421-432.
21. Forni G et al. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 1987; 138: 4033-4041.
22. Bosco M et al. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990; 145: 3136-3143.
23. Kurt-Jones EA, Fiers W, Pober JS. Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts. J Immunol 1987; 139: 2317-2324.
24. Kriegler M et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
25. Browning JL et al. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993; 72: 847-856.
26. Assenmacher M et al. Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man. Eur J Immunol 1996; 26: 263-267.
27. Kaplan D. Autocrine secretion and the physiological concentration of cytokines. Immunol Today 1996; 17: 303-304.
28. Lou J, Dayer JM, Grau GE, Burger D. Direct cell/cell contact with stimulated T lymphocytes induces the expression of cell adhesion molecules and cytokines by human brain microvascular endothelial cells. Eur J Immunol 1996; 26: 3107-3113.
29. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988; 18: 97-104.
30. Schuler T et al. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999; 189: 803-810.
31. Quentmeier H, Klaucke J, Muhlradt PF, Drexler HG. Role of IL-6, IL-2, and IL-4 in the in vitro induction of cytotoxic T cells. J Immunol 1992; 149: 3316-3320.
32. Liu B, Podack ER, Allison JP, Malek TR. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 1996; 156: 1117-1125.
33. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-512.
34. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257: 548-551.
35. Rossner P et al. Genetically modified tumour vaccines: insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene. Int J Oncol 1997; 10: 77-82.
36. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169: 1042-1049.
37. Lafferty KJ, Prowse SJ, Simeonovic CJ, Warren HS. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annn Rev Immunol 1983; 1: 143-173.
38. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7: 445-480.
39. Scwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-1356.
40. Boussiotis VA et al. Prevention of T cell anergy by signaling through the γ-chain of the IL-2 receptor. Science 1994; 266: 1039-1042.
41. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
42. Lin WC et al. Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol 1995; 155: 4805-4816.
43. Monastra G et al. Membrane form of TNF alpha induces both cell lysis and apoptosis in susceptible target cells. Cell Immunol 1996; 171: 102-110.
44. Lucas R et al. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 1997; 27: 1719-1725.
45. Marr RA et al. Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα. Gene Therapy 1997; 4: 1181-1188.
46. Soo Hoo W et al. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J Immunol 1999; 162: 7343-7349.
47. Sha WC et al. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 1988; 335: 271-274.
48. Kaye J et al. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J Exp Med 1983; 158: 836-856.
49. Matis LA et al. Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C. J Immunol 1983; 130: 1527-1535.
50. Baron JL et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177: 57-68.
51. Hu-Li J et al. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol 1989; 142: 800-807.